⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,716.78
+0.34%
Nasdaq 100
29,554.11
+0.08%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.60
−0.23%
NYSE:TSM
$427.55
+1.74%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,123.26
−0.42%
Brent
$108.91
−0.28%
BTC
$82,464.20
+0.76%
ETH
$2,437.15
+1.33%
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,716.78
+0.34%
Nasdaq 100
29,554.11
+0.08%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.60
−0.23%
NYSE:TSM
$427.55
+1.74%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,123.26
−0.42%
Brent
$108.91
−0.28%
BTC
$82,464.20
+0.76%
ETH
$2,437.15
+1.33%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Open
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
BridgeBio Pharma Inc · News · TradingHolo
Markets
›
United States
› NAS
› BBIO
B
BridgeBio Pharma Inc
NAS:BBIO
Healthcare
NASDAQ:NBI
NASDAQ:NQUSMG
$67.90
−0.06%
Live
In session · ≈
AED 249.36
· Market cap
$13.27B
· Next earnings
Wed 28 Oct
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
BBIO news
Headlines tagged to this company
DO
BridgeBio Pharma Price Target Cut to $91.00/Share From $94.00 by Citigroup
Dow Jones Newswires · 22 h ago
DO
BridgeBio Pharma Is Maintained at Overweight by Piper Sandler
Dow Jones Newswires · 26 h ago
GL
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 4 d ago
DO
BridgeBio Pharma Coverage Assumed by UBS at Buy
Dow Jones Newswires · 5 d ago
TR
BridgeBio Announces FDA Priority Review of NDA for Oral Infigratinib; PDUFA Feb 4, 2027
TradingView · 7 d ago
TR
BridgeBio Pharma, Inc. (BBIO) RWE Links Acoramidis to Lower Event Risk vs. Tafamidis
TradingView · 9 d ago
SE
BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug
Seeking Alpha · 9 d ago
GL
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
GlobeNewswire · 9 d ago
DO
BridgeBio Pharma Is Maintained at Overweight by Barclays
Dow Jones Newswires · 13 d ago
GL
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
GlobeNewswire · 14 d ago
GL
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
GlobeNewswire · 14 d ago
FI
Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
FinanceWire · 14 d ago
SE
BridgeBio nabs Priority Review for infigratinib for achondroplasia
Seeking Alpha · 14 d ago
RE
Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Reuters · 14 d ago
TR
BridgeBio Pharma, Inc. (BBIO) Gets FDA Priority Review for Infigratinib; PDUFA Feb. 4, 2027
TradingView · 14 d ago
GL
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
GlobeNewswire · 15 d ago
RE
Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels
Reuters · 15 d ago
TR
BridgeBio Pharma, Inc. (BBIO) Posts Positive Phase 3 Cardiac Biomarker Data; FDA Priority Review Ongoing
TradingView · 15 d ago
TR
Weekly Recap: Attruby $1B annual target and BBP-418 FDA review Nov 27, 2026
TradingView · 22 d ago
SE
BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study
seekingalpha · 27 d ago
More news →